Key facts
- This page summarizes Bradley Kroenig's Form 3 filing for MIRA PHARMACEUTICALS, INC. (MIRA).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Aug 2023, 17:58.
Bradley Kroenig - 02 Aug 2023 Form 3 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)
- Reporting relationship
- Director
- Issuer ticker
- MIRA
- Reported as of
- 02 Aug 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 02 Aug 2023, 17:58:23 UTC
- Next SEC filing
- 08 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michelle Yanez, Attorney-in-Fact for Bradley Kroenig
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Bradley Kroenig filed Form 3 for MIRA PHARMACEUTICALS, INC. (MIRA) on 02 Aug 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MIRA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 50,000
- Date
- 02 Aug 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MIRA
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $5.00
- Footnotes
- F1
MIRA
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $5.00
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option vested and became exercisable as to 23,334 shares on June 15, 2022 and 3,333 shares on June 15, 2023. 3,333 shares will become exercisable on June 15, 2024.
Footnote F2
The option vested and became exercisable in full on April 28, 2023.